Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase

Calgary, Alberta--(Newsfile Corp. - February 8, 2022) -  Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") is pleased to provide a corporate update on the operations of the business. Overview The Company is pursuing a well-known and proven to be effective strategy of redeveloping existing and approved drugs...

Marvel Biosciences Corp. Announces Change of Chief Financial Officer

Calgary, Alberta--(Newsfile Corp. - February 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") is pleased to announce the appointment of Harry Nijjar, CPA, CMA, as Chief Financial Officer of the Company, effective February 1, 2022, replacing Preston Maddin who left the Company effective January 31, 2022. Mr. Nijjar joined Malaspina Consultants Inc. in 2011 and is...

Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204

Calgary, Alberta--(Newsfile Corp. - December 16, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a multi-kilogram engineering run of its lead MB-204 asset by Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The engineering run material will be used for its...

Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound

Calgary, Alberta--(Newsfile Corp. - December 8, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its pre-clinical investigational new drug ("IND") enabling toxicology studies for its lead compound MB-204 with Pharmaron, Inc. ("Pharmaron"), with its...

Marvel Biosciences to Host Investor Webinar

Calgary, Alberta--(Newsfile Corp. - November 29, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the"Company" or "Marvel"), is pleased to announce that it will host an investor webinar via Zoom on Wednesday, December 1, 2021 at 1:00pm EST. The presentation will feature President and Chief Scientific Officer Mark Williams, who...

Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash

Calgary, Alberta--(Newsfile Corp. - November 23, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis ("NASH") using fibrosis and the non-alcoholic fatty liver...

Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds

Calgary, Alberta--(Newsfile Corp. - October 27, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or...

Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones

Calgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the"Company"or"Marvel"), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient ("API") of its lead drug MB-204, the Company has now entered an important milestone of...